|Bid||35.46 x 900|
|Ask||35.57 x 1800|
|Day's Range||33.56 - 35.92|
|52 Week Range||27.25 - 51.21|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 10, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||59.67|
Subscribe to Yahoo Finance Plus to view Fair Value for CCCCLearn more
C4 Therapeutics (CCCC) has been struggling lately, but the selling pressure may be coming to an end soon.
C4 Therapeutics, Inc. (CCCC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
– Phase 1/2 study of CFT7455, a Novel IKZF1/3 Degrader, Progressing with Data Expected in 2022; Trial-in-Progress Poster Accepted for Presentation at 63rd ASH Annual Meeting – – Investigational New Drug (IND) Application for CFT8634, a Degrader Targeting BRD9 for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors, On Track for Submission by YE 2021 – – Development Candidate CFT1946, a BRAF V600X Degrader, in IND-enabling Activities; C4T to Advance CFT1946 Independently – – On Track to Del